Press Releases

2012

January 5, 2012	Apogenix Raises € 7.5 Million to Further Advance APG101 to Treat Glioblastoma and other Tumors
January 3, 2012	Apogenix Receives Additional € 2.3 Million BMBF Grant as Partner of the Biotech Cluster Rhine-Neckar

2011

September 20, 2011	Apogenix Successfully Completes Patient Recruitment for Glioblastoma Phase II Trial with APG101
January 24, 2011	Apogenix Provides Update in the Ongoing Phase II Clinical Trial of APG101 to Treat Glioblastoma

2010

Mai 27, 2010	Data Published in “Nature” Confirms Development of APG101 to Treat Cancer
January 11, 2010	Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma

2009

November 16, 2009

Apogenix Receives Orphan Drug Designation for APG101 in the US and Positive Opinion on Orphan Product Designation in Europe

For further press releases please check our archive.